NSE / BSEHealthcare
β‚Ή378.15-4.50-1.18%
P/E58.0Mkt Capβ‚Ή25.38 K CrEV/EBITDA26.5

Syngene International Limited

P/E58.0Mkt Capβ‚Ή25.38 K CrEV/EBITDA26.5
Company Profile

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 15 Sept 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Strengths1

  • Operating margin of 27.5% exceeds Healthcare median (24.8%)

Concerns1

  • Operating margin declining for 3 consecutive years (29.0% β†’ 28.0% β†’ 27.0%)

Rule-based from financial data. Not advice.

Price Historyβ–Ό 43.63% over 1Y

Monthly Returns

Unlock Monthly Returns

Available on Pro and Institutional plans.

Sign up free

Year-to-Date ROI

Unlock Year-to-Date ROI

Available on Pro and Institutional plans.

Sign up free

Historical Volatility

Unlock Historical Volatility

Available on Pro and Institutional plans.

Sign up free

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή3.37 K Crβ–² 5.3%
EBITDA Growthβ€”
Net Profitβ‚Ή468.00 Crβ–² 0.4%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 2883.3%
Revenue CAGR 5Y9.7%
EBITDA CAGR 5Y4.4%
Net Profit CAGR 5Y2.5%
NP Growth 1Y0.4%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή3.37 K Crβ€”β‚Ή468.00 Crβ€”β€”10.1%5.3%0.4%
Mar 2024β‚Ή3.20 K Crβ€”β‚Ή466.00 Crβ€”β€”11.1%0.3%-1.5%
Mar 2023β‚Ή3.19 K Crβ€”β‚Ή473.00 Crβ€”β€”13.1%22.8%20.1%
Mar 2022β‚Ή2.60 K Crβ€”β‚Ή394.00 Crβ€”β€”12.0%19.4%-2.5%
Mar 2021β‚Ή2.18 K Crβ€”β‚Ή404.00 Crβ€”β€”14.3%8.3%-1.9%
Mar 2020β‚Ή2.01 K Crβ€”β‚Ή412.00 Crβ€”β€”19.0%10.2%24.5%
Mar 2019β‚Ή1.83 K Crβ€”β‚Ή331.00 Crβ€”β€”16.8%28.3%8.5%
Mar 2018β‚Ή1.42 K Crβ€”β‚Ή305.00 Crβ€”β€”17.7%18.5%6.3%
Mar 2017β‚Ή1.20 K Crβ€”β‚Ή287.00 Crβ€”β€”20.3%8.5%19.1%
Mar 2016β‚Ή1.11 K Crβ€”β‚Ή241.00 Crβ€”β€”23.5%28.7%37.7%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Free plan Β· showing 1 year of data.Upgrade

Consolidated Figures in USD Millions.

Unnamed: 0TTM
Revenue / Net Sales3,455
Total Expenses2,548
EBIT / Operating Profit906
OPM %26%
Other Income67
Finance Costs30
Depreciation & Amortisation377
Profit Before Tax567
Tax %-
Net Profit / PAT438
EPS (β‚Ή)10.87
Dividend Payout %-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Syngene International Limitedthis co.β‚Ή25.38 K Crβ‚Ή3.37 K Cr58.005.4826.545.3%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Syngene International Limited and the metrics that matter.

Browse the full Equiscale Academy